Caribou Biosciences, Inc. Share Price
CRBUCaribou Biosciences, Inc. Stock Performance
Open $1.91 | Prev. Close $1.88 | Circuit Range N/A |
Day Range $1.86 - $2.00 | Year Range $0.66 - $3.54 | Volume 46,493 |
Average Traded $1.92 |
Caribou Biosciences, Inc. Share Price Chart
About Caribou Biosciences, Inc.
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and autoimmune diseases in the United States and internationally. The company's lead product candidate include CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma, refractory systemic lupus erythematosus, lupus nephritis, and extrarenal lupus. It also develops CB-011, an anti-BCMA allogeneic CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.
Caribou Biosciences, Inc. Historical Data
| Day | Open | Close | Change % |
|---|---|---|---|
16-Mar-26 | $1.91 | $1.86 | +0.00% |
16-Mar-26 | $1.91 | $1.86 | -0.27% |
13-Mar-26 | $1.91 | $1.87 | +0.00% |
12-Mar-26 | $1.92 | $1.87 | -5.08% |
11-Mar-26 | $2.02 | $1.97 | -3.43% |
10-Mar-26 | $2.00 | $2.04 | +3.29% |
09-Mar-26 | $1.81 | $1.98 | +8.52% |